Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma plc (VRNA) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases that have significant unmet medical needs. Headquartered in both the United States and the United Kingdom, Verona Pharma is publicly traded on the NASDAQ Global Market and the London Stock Exchange.
The company's flagship product, Ensifentrine, is currently in development for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Ensifentrine is a dual inhibitor that has demonstrated potential in reducing inflammation and relaxing airway muscles, addressing critical gaps in the treatment of these chronic diseases. In addition to COPD and CF, Verona Pharma aims to expand its therapeutic pipeline to include treatments for other respiratory conditions such as asthma.
Verona Pharma's success is underpinned by a team of seasoned experts with extensive backgrounds in the discovery, development, and commercialization of respiratory therapies. The company has also forged strong partnerships with leading research institutions and advocacy organizations in the respiratory health sector. These collaborations have been instrumental in advancing their clinical programs and have garnered Verona Pharma several awards for innovation.
Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, which showed promising results in improving lung function and reducing symptoms in COPD patients. The company is now steering towards Phase 3 trials, marking a significant milestone in its mission to bring effective treatments to market.
Financially, Verona Pharma has demonstrated stability and growth, strengthening its financial flexibility through strategic funding rounds. This robust financial health supports ongoing research and development activities, ensuring sustained progress in their clinical programs. The company’s near-term goals include advancing Ensifentrine into late-stage clinical trials and exploring potential marketing authorizations.
For the latest updates on Verona Pharma’s research, financial performance, and upcoming milestones, stay tuned to the latest news and press releases.
Verona Pharma (VRNA) reported financial results for Q4 and full year 2021, highlighting significant progress in the Phase 3 ENHANCE program aimed at COPD treatment. Enrollment is complete for over 800 subjects in ENHANCE-2 and approximately 400 in ENHANCE-1. Positive safety results from a TQT study were disclosed, supporting a potential NDA submission in H1 2023. Financially, the company noted a revenue of $40 million from the Nuance agreement, a net loss of $55.6 million for the year, and a cash position of $148.4 million as of December 31, 2021.
Ligand Pharmaceuticals (NASDAQ: LGND) reported strong financial results for Q4 and the full year 2021, with total revenues of $72.5 million in Q4, up from $70.0 million in 2020, and $277.1 million for the year, a significant increase from $186.4 million in 2020. Royalties rose to $17.6 million in Q4, largely due to the Pelican platform. However, net income for Q4 was a loss of $5.0 million compared to a profit of $5.8 million the previous year. Ligand plans to spin off its OmniAb business, expected to generate substantial growth, and provided guidance for 2022 revenues of $147 million to $172 million.
Verona Pharma plc (Nasdaq: VRNA) will announce its fourth quarter and full year financial results for 2021 on March 3, 2022. The company, focused on innovative therapies for respiratory diseases, will host a conference call at 9:00 a.m. EST to discuss the results and corporate updates. Interested participants can join via specified phone numbers or a live webcast available on the company's website. Verona Pharma is advancing its product candidate, ensifentrine, currently in Phase 3 and Phase 2 clinical trials, aiming to offer unique treatment options for COPD and other respiratory conditions.
Verona Pharma, a clinical-stage biopharmaceutical company, has completed the enrollment of over 800 subjects in its Phase 3 ENHANCE-2 trial, which evaluates ensifentrine for chronic obstructive pulmonary disease (COPD) maintenance treatment. The top-line data is expected in the third quarter of 2022. CEO David Zaccardelli noted that reaching this milestone during the ongoing pandemic is significant. The trial aims to demonstrate the efficacy of ensifentrine, which combines bronchodilator and anti-inflammatory effects, in improving lung function and quality of life for COPD patients.
Verona Pharma (Nasdaq: VRNA) has completed screening for the ENHANCE-2 trial, enrolling 788 subjects with full enrollment expected by January's end. The Phase 3 program focuses on ensuring ensifentrine, a novel nebulized treatment for chronic obstructive pulmonary disease (COPD), shows efficacy and safety. Top-line data is anticipated in 2022, potentially leading to a New Drug Application with the FDA in early 2023. As of December 31, 2021, the company reported $148.4 million in cash, sufficient to cover operations through at least 2023.
Verona Pharma (Nasdaq: VRNA) announced that David Zaccardelli, Pharm. D., the CEO, will present an overview of the company at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand from 7:00 AM EST / 12:00 PM GMT on January 10, 2022. Interested parties can access a webcast of the event for 90 days via the company's website's Investors page. Verona Pharma focuses on developing innovative therapies for respiratory diseases, with its product candidate ensifentrine currently in Phase 3 development for COPD.
Verona Pharma has successfully completed a thorough QT study for its product candidate ensifentrine, showing no adverse effects on cardiac conduction in healthy individuals. This study is essential for the NDA submission for ensifentrine, aimed at treating COPD. The results will support the ongoing Phase 3 clinical trial program, ENHANCE, with expected data reporting in 2022. Ensifentrine, if approved, could become the first treatment combining bronchodilator and anti-inflammatory properties for respiratory diseases.
Verona Pharma reports its financial results for Q3 2021, revealing significant advancements in its ENHANCE Phase 3 clinical program for ensifentrine, targeting respiratory diseases. As of November 8, 2021, enrollment in ENHANCE-2 is approximately 90% complete, while the 48-week subset of ENHANCE-1 is about 95% enrolled. The company expects to conclude enrollment by year-end 2021 and release top-line data in mid-2022. Financially, revenues reached $40 million, supported by a new agreement with Nuance Pharma, and net profit improved to $11.1 million, a significant turnaround from a loss the previous year.
Verona Pharma plc (Nasdaq: VRNA) announced its participation in three investor conferences this November 2021. David Zaccardelli, CEO, will present at the Stifel Virtual Healthcare Conference on November 15, the Jefferies London Healthcare Conference on November 18, and the Piper Sandler Annual Virtual Healthcare Conference on November 29. The presentations will cover Verona's innovative respiratory therapies, including ensifentrine, which targets COPD and other respiratory diseases. Webcasts of the presentations will be available on the company's investor relations page.
Verona Pharma (Nasdaq: VRNA) will announce its financial results for Q3 and nine months ending September 30, 2021, on November 9, 2021, followed by a conference call at 9:00 a.m. EST. Investors can join via telephone or live webcast. Verona Pharma is developing ensifentrine, a novel therapy for respiratory diseases, currently in Phase 3 for COPD. The success of ensifentrine could make it the first dual-action treatment combining bronchodilation and anti-inflammatory effects. Further details available on their website.
FAQ
What is the current stock price of Verona Pharma (VRNA)?
What is the market cap of Verona Pharma (VRNA)?
What is Verona Pharma plc?
What is Ensifentrine?
What diseases does Verona Pharma target?
Where is Verona Pharma listed?
Who leads Verona Pharma?
What recent achievements has Verona Pharma made?
What are Verona Pharma’s near-term milestones?
Does Verona Pharma have any partnerships?
What awards has Verona Pharma received?
How can I stay updated on Verona Pharma?
